Maxim initiated coverage of Anixa Biosciences (ANIX) with a Buy rating and $10 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Anixa doses first patient in third cohort of Phase 1 clinical trial of CAR-T
- Anixa Biosciences: Advancing CAR-T Therapy and Cancer Vaccines with Strategic Trial Amendments and Robust Financial Position
- Anixa Biosciences announces approval of protocol amendment for CAR-T trial
- Director Shows Confidence in Anixa Biosciences with New Stock Purchase